PRESS RELEASE published on 12/13/2024 at 07:00, 1 year 10 months ago Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis FDA designates tolebrutinib as Breakthrough Therapy for non-relapsing SPMS based on positive HERCULES study results. Sanofi awaits regulatory review for this innovative medicine FDA Tolebrutinib HERCULES Study Breakthrough Therapy SPMS
BRIEF published on 12/11/2024 at 07:05, 1 year 10 months ago Sanofi's two combination vaccines against influenza and COVID-19 receive expedited review COVID-19 Sanofi Flu Combined Vaccines Expedited Review
PRESS RELEASE published on 12/11/2024 at 07:00, 1 year 10 months ago Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US Sanofi's two combination vaccine candidates targeting influenza and COVID-19 granted Fast Track designation in the US. Candidates combine licensed vaccines to assess safety and immunogenicity in older adults COVID-19 Sanofi Influenza Combination Vaccine Fast Track Designation
BRIEF published on 12/09/2024 at 20:11, 1 year 10 months ago Sarclisa Combinations Show Promise in Multiple Myeloma Treatment Clinical Study Multiple Myeloma Sarclisa MRD Negativity Treatment Efficacy
PRESS RELEASE published on 12/09/2024 at 20:06, 1 year 10 months ago Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New data presented at ASH demonstrates significant clinical benefit with Sarclisa-based combinations in newly diagnosed multiple myeloma patients, highlighting deep and durable responses and improved outcomes Multiple Myeloma Sarclisa ASH MRD Negativity Clinical Benefit
BRIEF published on 12/07/2024 at 17:35, 1 year 10 months ago Rilzabrutinib: Promising Advances in the Treatment of IPT Security Efficiency Phase III Rilzabrutinib TPI
PRESS RELEASE published on 12/07/2024 at 17:30, 1 year 10 months ago Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP Positive phase 3 study shows rilzabrutinib benefits in ITP patients. Results include platelet response, reduced bleeding, improved quality of life. Safety and efficacy highlighted Phase 3 Study Rilzabrutinib ITP BTK Inhibitor Patient Benefit
BRIEF published on 12/06/2024 at 07:35, 1 year 10 months ago Sanofi Publishes Revised Financial Statements Excluding Opella Financial Statements Biopharma Sanofi 2024 Results Opella
PRESS RELEASE published on 12/06/2024 at 07:30, 1 year 10 months ago Press Release: Availability of the revised financial statements for Sanofi excluding Opella Sanofi releases revised financial statements excluding Opella. The adjustments classify Opella as discontinued operations, aligning with Sanofi's transition to a biopharma company. Q4 2024 results expected on Jan 30, 2025 Sanofi Discontinued Operations Opella Revised Financial Statements Biopharma Company
PRESS RELEASE published on 10/25/2024 at 07:30, 2 years ago Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Published on 11/02/2026 at 23:15, 20 minutes ago ATHA Energy Announces Issuance of Common Shares in Satisfaction of US$25 Million Convertible Debenture Interest Payment Obligations
Published on 11/02/2026 at 22:30, 1 hour 5 minutes ago Sparton Files Morrison Mine N-I 43-101 Technical Report
Published on 11/02/2026 at 17:00, 6 hours 35 minutes ago PPX Mining Initiates Operating Permit Process for Igor Processing Plant
Published on 11/02/2026 at 17:00, 6 hours 35 minutes ago QNX Launches Global Developer Hackathon with $50,000 in Prizes to Accelerate Innovation in Mission-Critical Systems
Published on 11/02/2026 at 16:15, 7 hours 20 minutes ago ACCESS Newswire Launches SPOT, Seven AI Agents That Check Every Press Release Before Submission
Published on 11/02/2026 at 23:11, 23 minutes ago EQS-Adhoc: HUGO BOSS AG: HUGO BOSS UPDATES ITS FULL YEAR 2026 OUTLOOK
Published on 11/02/2026 at 22:05, 1 hour 30 minutes ago Abivax to Participate in Upcoming Fall Investor Conferences
Published on 11/02/2026 at 19:45, 3 hours 49 minutes ago HE Dr Sultan Al Jaber and Sam Altman highlight energy, AI and investment priorities at ADIPEC 2026 opening
Published on 11/02/2026 at 18:00, 5 hours 34 minutes ago Helvetia Asset Management Ltd adopts a unified market presence
Published on 11/02/2026 at 18:30, 5 hours 5 minutes ago Disclosure of transactions in own shares from October 26 to October 30, 2026
Published on 11/02/2026 at 18:17, 5 hours 17 minutes ago Reporting on share buyback transactions carried out between October 28 and October 29, 2026
Published on 11/02/2026 at 18:00, 5 hours 35 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 11/02/2026 at 17:59, 5 hours 35 minutes ago Saint-Gobain completes the divestment of its Dahl specialist distribution business in Sweden, Norway and Denmark